Abstract | OBJECTIVE: METHODS: Fifty-one subjects were included and 44 completed the study. The treatment continued for 12 weeks, including three treatment periods with no medication for 4 weeks, administration of low dose methylphenidate (up to 5 mg × 3) for 4 weeks and normal dose methylphenidate (up to 20 mg × 3) for a further 4 weeks. The patients were randomized into three groups where all groups were given all treatments. RESULTS: Significantly reduced mental fatigue, assessed with the Mental Fatigue Scale (MFS) and increased information processing speed (coding, WAIS-III), were detected. The SF-36 vitality and social functioning scales were also improved significantly. Pain was not reduced by methylphenidate. The positive effects of treatment were dose-dependent, with the most prominent effects being at 60 mg methylphenidate/day spread over three doses. Observed side-effects were increased blood pressure and increased heart rate. CONCLUSIONS:
|
Authors | B Johansson, A-P Wentzel, P Andréll, C Mannheimer, L Rönnbäck |
Journal | Brain injury
(Brain Inj)
Vol. 29
Issue 6
Pg. 758-65
( 2015)
ISSN: 1362-301X [Electronic] England |
PMID | 25794299
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adult
- Brain Injuries
(drug therapy, psychology)
- Cognition
(drug effects)
- Dose-Response Relationship, Drug
- Female
- Humans
- Male
- Mental Fatigue
(drug therapy, psychology)
- Methylphenidate
(therapeutic use)
- Middle Aged
- Pain
(drug therapy)
- Treatment Outcome
|